Metastasis of ovarian cancer to the breast: A report of two cases and a review of the literature

Tempfer, Clemens B.; Fizazi, Nariman El; Ergonenc, Hassan; Solaß, Wiebke

doi:10.3892/ol.2016.4514

Cited by 26 publications

(29 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies have reported that up to 95% of serous papillary carcinomas exhibit nuclear expression of WT-1and membrane expression of CA125, which is only present in <10% of different types of breast cancer ( 35 – 37 ). A more recent study also suggested the value of GATA-3 and PAX-8 as biomarkers for breast cancer ( 38 , 39 ). Consistent with a previous study ( 3 ), the results of the current study indicate that no single marker is absolutely specific and its expression is always variable between primary and metastatic lesions, particularly in tissue biopsies.…”

Section: Discussionmentioning

confidence: 93%

Characteristics of breast metastases from non-breast solid tumors in 22ï¿½patients from a southern Chinese population

Sun

Chen

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Breast metastases from solid non-breast tumor types are rare; however, they should be always considered in the differential diagnosis of a breast lesion owing to the associated poor patient prognosis and the requirement of different therapeutic strategies compared with those used to treat primary breast cancer. The aim of the current study was to summarize the characteristics of metastases to the breast in a southern Chinese population. The medical records and pathological sections of 22 patients with pathologically confirmed extra-mammary metastases to the breast that presented to Sun Yat-sen University Cancer Center between January 2000 and December 2015 were retrospectively reviewed. The median age of onset for breast metastasis was 43 years (range, 10–62 years) and 19 (86.4%) patients had a known history of a primary tumor. The mean interval from diagnosis of the primary tumor to breast metastasis was 16.5 months (range, 6–56 months). A unilateral (45.5% left, 36.4% right), upper outer quadrant (15/22, 68.2%) lesion of the breast was most frequently initially detected by self-checking (63.6%). The most common origin of the primary tumor was the lung (22.7%). Nasopharyngeal carcinoma accounted for a high proportion of the metastases (18.2%). The median duration of survival from the time of diagnosis of a breast metastasis was 14 months (range, 2–74 months). A total of 10 patients (45.5%) succumbed to the disease. The results also indicated that overall survival in patients that underwent surgery was improved compared with patients who did not undergo surgery. The results of the present study demonstrated that clinical history, imaging findings, pathology from the primary tumor and immunostaining were required in combination to establish an accurate diagnosis. Further investigation into the improvement of the prognosis of patients with metastases to the breast following surgery is required.

show abstract

Section: Discussionmentioning

confidence: 93%

Characteristics of breast metastases from non-breast solid tumors in 22ï¿½patients from a southern Chinese population

Sun

Chen

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…[ 5 ] However, metastasis from extramammary malignancy to the breast is a rare condition, accounting for only 0.3% of all breast malignancies. [ 3 ] Furthermore, the patient in this case study is diagnosed with borderline tumor with micro-invasive carcinoma of ovary with low malignant potential, which appears to be even more rare. Breast metastatic lesions are typically described as appearing quite benign on both mammographic and clinical examinations.…”

Section: Discussionmentioning

confidence: 99%

“…[ 41 ] Immunohistochemical markers are also significant and the combined use of multiple markers can provide more sufficient diagnostic evidence. [ 3 ] WT-1, PAX-8, and GCDFP-15 play a major role in differentiation between primary breast tumors and breast metastasis from ovarian tumors. WT-1 is mainly expressed in ovarian cancer, and less than 10% of primary breast cancers are positive for WT-1, which are usually weakly expressed or focally expressed.…”

Section: Discussionmentioning

confidence: 99%

“…Metastasis of ovarian tumors to breast is a very rare condition. [ 1 , 2 ] Ascites, abdominal pain, abdominal distension are the most common symptom of ovary carcinoma, [ 3 ] however, the breast lump as the first clinical presentation for ovarian carcinoma is rarely seen. Breast metastasis from serous borderline tumor with micro-invasive carcinoma of ovary has never been reported in literature.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Metastatic serous borderline tumor with micro-invasive ovarian carcinoma presenting as a breast lump

Dong¹,

Xie²,

Xue³

et al. 2020

Medicine

View full text Add to dashboard Cite

Rationale: Breast metastasis from serous borderline tumor with micro-invasive carcinoma of ovary is a very rare condition. The breast lump as the only clinical presentation is rarely seen in ovarian carcinoma, which may lead to be misdiagnosed, and the mechanism of breast metastasis from ovarian tumors in early stage still needs to be explored. Differentiation from primary breast cancer and extramammary malignancy is crucial because the treatment and prognosis are significantly different. Patient concerns: A 33-year-old female presented with a painless, movable, 1.0 × 1.0 cm lump in the upper outer quadrant of the right breast for a month. Diagnoses: Breast metastasis of serous borderline tumor with micro-invasive ovarian carcinoma confirmed by pathology and immunohistochemistry. Interventions: The patient underwent lumpectomy, bilateral ovarian tumor stripping operation and prophylactic chemotherapy. Outcomes: No signs of recurrence have been detected in 1.5 years of follow-up. Lessons: Distant metastasis may occur in early stage of ovarian carcinoma. It is important to determine the origin of the primary tumor and develop an effective treatment strategy for patients. Imaging findings and pathological diagnostic criteria are important to accurately differentiate between metastasis and primary breast lesions, which may improve the patient's outcomes.

show abstract

“…Ovarian cancer exhibits high rates of mortality compared with other gynecological malignances ( 1 ). Investigations into the pathogenesis of ovarian cancer have reported that diagnosis occurs within the later stages of pathogenesis, which has been associated with lower overall survival rates ( 2 , 3 ).…”

Section: Introductionmentioning

confidence: 99%

Pegylated liposomal‑paclitaxel induces ovarian cancer cell apoptosis via TNF‑induced ERK/AKT signaling pathway

Yin

et al. 2018

Mol Med Report

View full text Add to dashboard Cite

Ovarian cancer is one of the most common gynecological types of cancer and is characterized by a relatively high incidence and high mortality rate. Evidence has demonstrated that paclitaxel (PTX) is an effective therapeutic treatment for human ovarian cancer. In the present study, the inhibitory effects of pegylated liposomal (PL)-PTX on the growth of ovarian cancer cells were investigated in vitro; a CAOV-3-bearing mouse model was established to investigate the in vivo effects of PL-PTX on ovarian tumor growth. In the present study, the underlying mechanism of tumor necrosis factor (TNF)-induced inhibition of extracellular signal-regulated kinase (ERK)/protein kinase B (AKT) signaling pathway mediated by PL-PTX was analyzed within ovarian cancer cells. The results of the present study revealed that PL-PTX significantly inhibited the growth and aggressiveness of ovarian cancer cells in vitro and in vivo and apoptotic ability increased upon administration of PL-PTX. The expression levels of caspase-3/9 were significantly upregulated within PL-PTX-treated ovarian cancer cells. The expression and phosphorylation levels of ERK and AKT were markedly increased in response to PL-PTX treatment. In addition, the inhibitory effects of PL-PTX on ovarian cancer cells were eliminated by neutralizing antibodies against TNF. The observations of the present study revealed that PL-PTX induced ovarian cell apoptosis via the TNF-dependent pathway, which was significantly inhibited with the employment of antibodies against TNF. In vivo analysis demonstrated that PL-PTX treatment significantly inhibited ovarian tumor growth and prolonged the survival of tumor bearing mice. In conclusion, the findings of the present study have provided an insight into the potential mechanism of PL-PTX-induced apoptosis of ovarian cancer cells. As PL-PTX has been reported to induce ovarian tumor cell apoptosis via the TNF-induced ERK/AKT signaling pathway, PL-PTX may serve as an efficient anticancer drug for the treatment of ovarian cancer.

show abstract

Metastasis of ovarian cancer to the breast: A report of two cases and a review of the literature

Cited by 26 publications

References 24 publications

Characteristics of breast metastases from non-breast solid tumors in 22ï¿½patients from a southern Chinese population

Characteristics of breast metastases from non-breast solid tumors in 22ï¿½patients from a southern Chinese population

Metastatic serous borderline tumor with micro-invasive ovarian carcinoma presenting as a breast lump

Pegylated liposomal‑paclitaxel induces ovarian cancer cell apoptosis via TNF‑induced ERK/AKT signaling pathway

Contact Info

Product

Resources

About